Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Small Cell Lung Carcinoma 2Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Metastatic Bladder Urothelial Carcinoma 1Leiomyosarcoma 1Hereditary Sensory and Autonomic Neuropathies 1Fallopian Tube Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1

Interventions

Gemcitabine 13Doxorubicin 8Docetaxel 7Trabectedin 5pazopanib 4Nivolumab 4Temozolomide 3Specimen Handling 3Sorafenib 3rucaparib 2pembrolizumab 2liposomal doxorubicin 2durvalumab 2brostallicin 2Sunitinib 2Radiotherapy 2Radiation Dose Hypofractionation 2Magnetic Resonance Spectroscopy 2Letrozole 2Ifosfamide 2Dacarbazine 2Bevacizumab 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1talimogene laherparepvec 1sotigalimab 1soblidotin 1saracatinib 1rubitecan 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leiomyosarcoma × berzosertib × Clear all
NCT03718091 2023-07-07

M6620 (VX-970) in Selected Solid Tumors

Massachusetts General Hospital

Phase 2 Completed
30 enrolled 15 charts
Sarcoma

Leiomyosarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡